TL;DR
This study provides the first comprehensive pan-cancer analysis of Matrix Metallopeptidase 7 (MMP7), revealing its widespread, yet varied, role in human cancers. By integrating multiple large-scale datasets, the research identifies MMP7 as a potential prognostic marker and therapeutic target, highlighting its association with tumor progression, immune infiltration, and key cellular pathways.
What Problem Does This Paper Address?
While MMP7 has been implicated in the development and progression of various cancers, a systematic, large-scale analysis across a broad spectrum of human tumors was lacking. Previous research often focused on individual cancer types or specific aspects of MMP7's function. This paper aims to fill that gap by providing a comprehensive pan-cancer perspective on MMP7's expression, genetic alterations, prognostic value, and its relationship with the tumor microenvironment, using extensive clinical data. Understanding these multifaceted roles is crucial for developing targeted therapies and improving patient outcomes.
Methods
The researchers employed a multi-pronged approach, leveraging several publicly available bioinformatics databases and tools:
- TIMER2.0 and GEPIA2: Used for analyzing differential gene expression between tumor and normal tissues across various TCGA cancer types, as well as exploring correlations with pathological stages and survival data.
- UALCAN: Utilized to examine MMP7 protein expression levels in tumor tissues compared to normal tissues, specifically using the CPTAC dataset.
- cBioPortal: Employed for investigating genetic alterations of MMP7, including mutation frequencies, types, and copy number alterations (CNA) across TCGA cancers.
- STRING: Used to predict protein-protein interactions (PPI) involving MMP7, identifying potential interacting partners.
- Metascape: Applied for gene annotation and enrichment analysis (KEGG pathways and Gene Ontology) of MMP7-interacting and MMP7-correlated genes to understand underlying molecular mechanisms.
- OSppc and LOGpc: Employed for pan-cancer differential expression and prognosis analysis at the protein level.
- Immunohistochemistry (IHC): Performed on a subset of stomach adenocarcinoma (STAD) and colon adenocarcinoma (COAD) tissues to validate MMP7 protein expression findings.
Datasets
The study primarily utilized data from:
- The Cancer Genome Atlas (TCGA): A comprehensive resource for genomic and clinical data from a wide range of cancer types.
- Gene Expression Omnibus (GEO): Another public repository for gene expression data.
- Genotype-Tissue Expression (GTEx) project: Provided normal tissue data for comparison when TCGA had limited or no normal samples.
- Clinical Proteomic Tumor Analysis Consortium (CPTAC): Used for protein expression analysis.
No new benchmarks were introduced; instead, the study integrated and analyzed existing large-scale datasets.
Key Insights and Ideas
- MMP7 is a double-edged sword: While generally upregulated in many cancers, suggesting an oncogenic role, it's notably downregulated in breast, kidney, and liver cancers, hinting at context-dependent functions.
- Beyond expression: Genetic alterations matter: MMP7's genetic alterations, particularly missense mutations and gene amplification, are prevalent and can influence prognosis, though the specific impact varies by cancer type.
- The tumor microenvironment connection: MMP7 expression is strongly linked to the presence of cancer-associated fibroblasts (CAFs) and immune cells like dendritic cells and macrophages, suggesting it plays a role in shaping the tumor's immune landscape.
- Pathway insights point to fundamental processes: Functional enrichment analysis highlights "RNA degradation" and "DNA damage checkpoints" as key pathways potentially influenced by MMP7, suggesting its involvement in fundamental cellular maintenance and repair mechanisms that can go awry in cancer.
Key Results
- Differential Expression: MMP7 was significantly upregulated in many TCGA cancer types (e.g., cholangiocarcinoma, colon adenocarcinoma, lung adenocarcinoma) but downregulated in others (e.g., invasive breast carcinoma, kidney chromophobe, liver hepatocellular carcinoma). Protein expression mirrored this trend in analyzed tissues.
- Prognostic Value: High MMP7 expression was associated with poorer overall survival (OS) in several cancers, including KIRC, LAML, LGG, and LIHC. Conversely, low MMP7 expression indicated better disease-free survival (DFS) in KIRC, LGG, SARC, and THYM.
- Genetic Alterations: Gene amplification was the most common alteration type in many TCGA cancers. Missense mutations were the primary type of genetic alteration, with a specific mutation (F65L) noted in several cancer types.
- Immune Cell Infiltration: MMP7 expression showed significant positive correlations with CAFs in most TCGA cancers. It also correlated positively with dendritic cells and macrophages in specific tumor types. Interestingly, a negative correlation with M2 macrophages in breast cancer was observed.
- Pathway Enrichment: KEGG pathway analysis identified "RNA degradation" as a significantly enriched pathway, while GO analysis highlighted terms related to enzyme inhibition and RNA processing.
Limitations and Future Work
The authors acknowledge that:
- Database and sample size variations: Discrepancies in MMP7 expression findings between gene and protein levels, or across different studies, may be due to variations in databases, sample sizes, and experimental settings.
- Limited protein data: CPTAC data for protein expression was only available for a few cancer types.
- Further validation needed: The prognostic significance of specific genetic alterations (e.g., F65L mutation) requires further investigation.
- OV expression discrepancy: The observed gene expression upregulation of MMP7 in ovarian cancer was not replicated at the protein level, suggesting a need for further confirmation with larger datasets.
Future work could focus on validating these findings in larger, independent cohorts, exploring the precise molecular mechanisms by which MMP7 influences RNA processing and DNA damage checkpoints, and investigating MMP7 as a therapeutic target, particularly in cancers where it is upregulated and associated with poor prognosis.
Summary updated